Compare Dr. Reddys with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs GLENMARK PHARMA - Comparison Results

DR. REDDYS LAB     Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the pharmaceutical value chain - basic research, finished dosages, generics, bulk actives, and biotechnology. The company's business is mainly organized into Global g... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB GLENMARK PHARMA DR. REDDYS LAB/
GLENMARK PHARMA
 
P/E (TTM) x 39.3 17.1 229.6% View Chart
P/BV x 5.4 2.8 191.3% View Chart
Dividend Yield % 0.5 0.4 137.9%  

Financials

 DR. REDDYS LAB   GLENMARK PHARMA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-20
GLENMARK PHARMA
Mar-19
DR. REDDYS LAB/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs3,363712 472.6%   
Low Rs2,352484 486.4%   
Sales per share (Unadj.) Rs1,054.2349.6 301.5%  
Earnings per share (Unadj.) Rs121.932.8 371.9%  
Cash flow per share (Unadj.) Rs190.244.3 429.1%  
Dividends per share (Unadj.) Rs25.002.00 1,250.0%  
Dividend yield (eoy) %0.90.3 261.4%  
Book value per share (Unadj.) Rs938.7198.6 472.6%  
Shares outstanding (eoy) m166.17282.17 58.9%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.71.7 158.6%   
Avg P/E ratio x23.418.2 128.6%  
P/CF ratio (eoy) x15.013.5 111.4%  
Price / Book Value ratio x3.03.0 101.2%  
Dividend payout %20.56.1 336.1%   
Avg Mkt Cap Rs m474,831168,625 281.6%   
No. of employees `00021.712.0 179.9%   
Total wages/salary Rs m33,80220,561 164.4%   
Avg. sales/employee Rs Th8,091.08,196.0 98.7%   
Avg. wages/employee Rs Th1,561.31,708.1 91.4%   
Avg. net profit/employee Rs Th935.8768.5 121.8%   
INCOME DATA
Net Sales Rs m175,17098,655 177.6%  
Other income Rs m6,2062,081 298.2%   
Total revenues Rs m181,376100,736 180.1%   
Gross profit Rs m24,42115,858 154.0%  
Depreciation Rs m11,3483,259 348.2%   
Interest Rs m9833,346 29.4%   
Profit before tax Rs m18,29611,335 161.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m5610-   
Extraordinary Inc (Exp) Rs m01,672 0.0%   
Tax Rs m-1,4033,756 -37.3%   
Profit after tax Rs m20,2609,250 219.0%  
Gross profit margin %13.916.1 86.7%  
Effective tax rate %-7.733.1 -23.1%   
Net profit margin %11.69.4 123.4%  
BALANCE SHEET DATA
Current assets Rs m125,99166,968 188.1%   
Current liabilities Rs m72,14140,211 179.4%   
Net working cap to sales %30.727.1 113.3%  
Current ratio x1.71.7 104.9%  
Inventory Days Days7383 87.7%  
Debtors Days Days10581 129.0%  
Net fixed assets Rs m83,85433,322 251.6%   
Share capital Rs m831282 294.5%   
"Free" reserves Rs m155,15755,770 278.2%   
Net worth Rs m155,98856,052 278.3%   
Long term debt Rs m1,30435,738 3.6%   
Total assets Rs m232,253132,888 174.8%  
Interest coverage x19.64.4 447.0%   
Debt to equity ratio x00.6 1.3%  
Sales to assets ratio x0.80.7 101.6%   
Return on assets %9.19.5 96.5%  
Return on equity %13.016.5 78.7%  
Return on capital %12.617.8 70.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m84,19362,998 133.6%   
Fx outflow Rs m39,61622,859 173.3%   
Net fx Rs m44,57740,140 111.1%   
CASH FLOW
From Operations Rs m29,84113,242 225.4%  
From Investments Rs m-4,923-6,990 70.4%  
From Financial Activity Rs m-25,159-7,387 340.6%  
Net Cashflow Rs m-266-2,971 9.0%  

Share Holding

Indian Promoters % 25.5 48.3 52.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 6.9 78.3%  
FIIs % 35.3 34.4 102.6%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 10.5 145.7%  
Shareholders   75,885 56,727 133.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   SHASUN PHARMA  CIPLA  TORRENT PHARMA  SUVEN LIFE SCIENCES  WYETH  

Compare DR. REDDYS LAB With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 202 Points Lower; Britannia and Mahindra & Mahindra Among Top Nifty Losers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended lower.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 132.5% (Quarterly Result Update)

Sep 1, 2020 | Updated on Sep 1, 2020

For the quarter ended June 2020, GLENMARK PHARMA has posted a net profit of Rs 3 bn (up 132.5% YoY). Sales on the other hand came in at Rs 23 bn (up 0.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 64.0% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

Top 3 Nifty ETFs to Buy Now(Fast Profits Daily)

Apr 20, 2021

In this video I tell you the three Nifty ETFs I think are the best.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

11x Bankruptcy to Bluechip Stock: A Rare India Revival Story(Profit Hunter)

Apr 16, 2021

There is no stopping this 11-bagger stock from significant upside.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Apr 23, 2021 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS